undamentalytics Newsletter
Sign in

Xeris Biopharma Holdings, Inc. balance sheet

At the end of fiscal 2025, Xeris Biopharma Holdings, Inc. had total assets of $384m, total liabilities of $370m and shareholders' equity of $13.7m. It held $111m in cash against $234m of debt: net debt of $123m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents38671226772111122
Receivables7173139405158
Inventory8182539486981
Total current assets152143187156168240275
Goodwill0232323232323
Total assets159304345323323384412
Accounts payable39512239
Total current liabilities28797495100110190
Short-term debt———015064
Long-term debt8788187191217220189
Total debt8788197199249234253
Total liabilities125209299329353370422
Shareholders' equity349545−7−3014−10
Net debt (negative = net cash)492175131177123131
Shares outstanding——136m138m149m166m174m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EOLS vs XERSIRWD vs XERSHROW vs XERSINVA vs XERS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xeris Biopharma Holdings, Inc.